Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2017

Nov 03, 2017

SELL
$5.95 - $8.26 $7,883 - $10,944
-1,325 Closed
0 $0
Q2 2017

Aug 11, 2017

BUY
N/A
1,325
1,325 $8,000

Others Institutions Holding CBAY

About CymaBay Therapeutics, Inc.


  • Ticker CBAY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,677,904
  • Description
  • CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...
More about CBAY
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.